About the Company
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMGN News
ImmunoGen’s stock rockets to 23-year high after AbbVie’s $10.1 billion buyout deal
Shares of ImmunoGen Inc. rocketed toward a 23-year high Thursday after the biotechnology company agreed to be acquired buy AbbVie Inc. in a cash deal valued at $10.1 billion. AbbVie said the deal ...
Immunogen Inc (IMU.DU)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal
AbbVie said the Food and Drug Administration had fully approved its ovarian cancer treatment, which was acquired in its recently closed purchase of biotech company ImmunoGen. The drug company ...
Cancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventions
See Phigenix, Inc. v. Immunogen, Inc., Case IPR-2014-00676, Final Written Decisions dated October 27, 2015 (Paper 39). Independent claim 1 of the ‘856 patent recites: 1. An immunoconjugate comprising ...
ArriVent Appoints Kristine Peterson to its Board of Directors
“I am excited to work alongside ArriVent’s talented management team and Board of Directors to help address the unmet needs of cancer patients,” said Ms. Peterson. “I look forward to providing ...
Lilly revives ImmunoGen ADC pact with new $1.7bn deal
ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.
Emergence of ADCs as the “hot, new technology”
The cycle from hot to cold to hot again can take 10-15 years and a new technology may go through more than one such cycle (as ...
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call April 26, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $2.31, expectations were $2.26.
AbbVie: The Inevitable Is Happening
AbbVie's shares dropped last week due to concerns about Humira erosion and despite ABBV beating revenue and EPS expectations.
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
AbbVie's acquisition of ImmunoGen strengthens its oncology pipeline and solid tumor capabilities. Robust financial ...
APPLE INC.
ImmunoGen Inc, Nokia Corp, Dollar Thrifty Automotive Group, Research In Motion, Apple Inc, Hewlett-Packard, Partner Communications and Tata Motors Ltd. are among the companies whose shares are ...
Loading the latest forecasts...